Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study, the researchers found that infectious dermatologic conditions were most common among renal transplant recipients, with viral warts being the prevalent infectious condition, while increasing age and sex were associated with varying odds of developing different dermatologic issues.

In this study, researchers at a tertiary cancer center observed that many male germ cell tumor survivors experienced degrees of hypogonadism and erectile dysfunction, highlighting the clinical need to monitor endocrine health in cancer survivors.

This study found that in patients undergoing allogeneic hematopoietic stem-cell transplantation, older age significantly increases the risk of hemorrhagic cystitis, especially in males, who are also affected by prostatic hyperplasia.

This study observed that both dutasteride and finasteride affected penile morphology in normotensive and hypertensive rats, with more pronounced changes in hypertensive animals, especially when treated with dutasteride.

This study reports that hyperuricemia, the second most common metabolic disease after diabetes, is linked to numerous health issues, especially in males, and recommends lifestyle modifications as an effective management strategy, highlighting the lack of consensus on uric acid thresholds necessitating drug therapy.

This review discusses underactive bladder, highlighting its poorly understood nature, diagnostic challenges, and limited treatment effectiveness, and reports no new clinical results.

This chapter reviews the male accessory sex glands in rats and their responses to hormonal influences, detailing common spontaneous changes and effects of compounds, but it provides no new experimental findings.

This report discusses Titanflow as a potential improvement in male urinary health by focusing on the detrusor muscle rather than prostate size, suggesting it may offer relief where other supplements have limited effectiveness.

This review discusses the long-term effects of gender affirming hormone therapy and reports no new clinical findings, recommending a shared decision-making approach to balance benefits and risks for transgender individuals.

This review discusses the prevalence and treatment of benign prostatic hyperplasia and reports no new findings; it emphasizes considering side effects and comorbidities in therapy choices.

This review discusses the potential mechanisms by which androgens may elevate blood pressure, particularly through impacts on the renin-angiotensin system, but reports no new experimental results.

This study found that xerosis and pruritus are prevalent in patients with chronic renal failure undergoing hemodialysis, highlighting the importance of early recognition of skin issues to alleviate discomfort and reduce complications.

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

This study found that both finasteride and dutasteride led to morphological and functional kidney damage in rats, with more severe effects observed in the dutasteride group.

This review discusses lesser-known concerns in transgender dermatology, including neovaginal issues, neoplastic and autoimmune conditions, and the effects of unapproved injectable substances, but reports no new clinical findings.

This review examines microbial production and applications of gluconic acid, focusing on the enzymatic processes involved, and offers no new experimental results.

This study found that nail and hair changes were predominantly observed in patients with stage 5D chronic kidney disease, with the most common changes being half and half nails and sparse scalp hair.

This article discusses advancements and future directions in the treatment of benign prostatic hyperplasia, highlighting ongoing clinical trials of novel techniques, but it reports no new clinical results.

This study found that metabolic syndrome significantly affects the response to benign prostatic hyperplasia medications, impacting clinical outcomes such as symptom scores, prostate volume, and quality of life among male patients.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This study found that men aged 60 or older with postoperative urinary retention were more likely to undergo bladder outlet procedures within three years.

In this study, higher urethral prostate-specific antigen (urPSA) levels in men after radical prostatectomy were associated with higher androgenic alopecia scores and higher postoperative PSA.

This study found that finasteride improved urodynamic measures of obstruction in men with benign prostatic enlargement and lower urinary tract symptoms, with continued improvement over two years of treatment.

This Cochrane review reports that 5-alpha reductase inhibitors may slightly reduce urological symptoms and acute urinary retention risk compared to placebo, with a possible small reduction in surgical intervention need compared to alpha blockers.

This study observed that gender-affirming hormone therapy differentially affects metabolism in mice, with the specific metabolic impacts dependent on the type of hormonal treatment used.

This study found that vaginal surgical interventions for genital prolapse or urinary incontinence did not significantly alter the quality of sexual life in women, with a portion reporting improvement and others experiencing no change or decreased libido.

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This study found that age is the most significant risk factor for hemorrhagic cystitis after hematopoietic stem-cell transplantation, with additional risk factors including cyclophosphamide-based prophylaxis and, among male recipients, prostatic hyperplasia.